SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
RADNOR, Pa., April 24, 2021 The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Vroom, Inc. in.
Share:
RADNOR, Pa., April 24, 2021 (GLOBE NEWSWIRE) The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of New York against 3D Systems Corp. (NYSE:DDD) ( 3D Systems ) on behalf of those who purchased or acquired 3D Systems securities
between May 6, 2020 and March 1, 2021, inclusive (the Class Period ).
Deadline Reminder: Investors who purchased or acquired 3D Systems securities
during the Class Period may,
no later than June 8, 2021
, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail atinfo@ktmc.com;
Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases.
The complaint alleges that throughout the Class Period, the defendants failed to disclose that: (1) Emergent s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) these longstanding contamination risks and quality control issues at Emergent s facility led to a string of U.S. Food and Drug Administration citations; (3) Emergent previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (4) as a result of the foregoing, the defendants public statements about Emergent s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.